Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2013
Event: Regulatory approval announcement regarding the company's product UPLYSO (alphataliglicerase).
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing a specific corporate event. It does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial metric.
Material Changes
Regulatory Milestone: On March 18, 2013, the Brazilian National Health Surveillance Agency (ANVISA) granted regulatory approval for UPLYSO (alphataliglicerase).
Indication: Long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease.
Market Context: Gaucher disease is a rare lysosomal storage disorder affecting approximately 10,000 people worldwide. UPLYSO is marketed as ELELYSO (taliglucerase alfa) outside of Latin America.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the approval but does not include specific forward-looking guidance, financial outlook, or detailed risk factors within the text of this 8-K.
Unusual Items: None reported in this specific filing.
Investor Verification Checklist
- Verify the commercial launch timeline for UPLYSO in Brazil following ANVISA approval.
- Review the full text of the press release (Exhibit 99.1) for details on the partnership with Pfizer Inc.
- Assess the potential revenue impact of the Brazilian market relative to the company's global strategy.
- Confirm the distinction between the product names UPLYSO (Latin America) and ELELYSO (global) for regulatory tracking.